Compare FOFO & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOFO | ACET |
|---|---|---|
| Founded | 2017 | 1947 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.2M | 71.3M |
| IPO Year | 2025 | N/A |
| Metric | FOFO | ACET |
|---|---|---|
| Price | $5.74 | $8.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $65.33 |
| AVG Volume (30 Days) | 64.6K | ★ 204.6K |
| Earning Date | 03-13-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $3,117,608.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.35 | ★ N/A |
| Revenue Growth | ★ 1597.65 | N/A |
| 52 Week Low | $4.53 | $7.15 |
| 52 Week High | $68.00 | $17.44 |
| Indicator | FOFO | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 33.64 | 74.40 |
| Support Level | $5.56 | $8.18 |
| Resistance Level | $6.14 | $9.00 |
| Average True Range (ATR) | 0.50 | 0.47 |
| MACD | 0.09 | -0.19 |
| Stochastic Oscillator | 16.82 | 58.46 |
Hang Feng Technology Innovation Co Ltd is committed to providing comprehensive corporate management consulting and asset management services, tailored to address the specific needs of each client. Its goal is to empower its clients to design, implement, and achieve their unique business and investment objectives. Its business consists of two main segments: (i) corporate management consulting services and (ii) asset management services. The corporate management consulting services include Management consulting, and Regulatory compliance and governance consulting.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.